Claro Advisors
VRTX icon

Claro Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Claro Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13M Buy
2,154
+709
+49% +$363K 0.11% 169
2026
Q2 		$718K Sell
1,445
-161
-10% -$71.4K 0.08% 208
2026
Q1 		$717K Sell
1,606
-99
-6% -$46.2K 0.09% 186
2025
Q4 		$773K Sell
1,705
-13
-0.8% -$5.6K 0.11% 171
2025
Q3 		$673K Sell
1,718
-828
-33% -$346K 0.1% 179
2025
Q2 		$1.13M Sell
2,546
-392
-13% -$181K 0.19% 104
2025
Q1 		$1.42M Sell
2,938
-137
-4% -$63.8K 0.19% 97
2024
Q4 		$1.24M Buy
3,075
+650
+27% +$301K 0.17% 110
2024
Q3 		$1.13M Buy
2,425
+471
+24% +$226K 0.15% 135
2024
Q2 		$916K Buy
1,954
+591
+43% +$257K 0.14% 142
2024
Q1 		$570K Buy
1,363
+98
+8% +$41.4K 0.1% 215
2023
Q4 		$515K Buy
1,265
+56
+5% +$20.7K 0.11% 210
2023
Q3 		$420K Buy
1,209
+143
+13% +$50K 0.11% 221
2023
Q2 		$375K Buy
+1,066
New +$359K 0.09% 235
2019
Q1 		– Sell
-343
Closed -$66K – 920
2018
Q4 		$66K Buy
+343
New +$59.4K 0.05% 296

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Claro Advisors's VRTX Position: Q3 2026 in Review

Claro Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 49% in Q3 2026, buying an estimated $363K and bringing the position to 2,154 shares worth $1.13M. The position accounts for 0.11% of the portfolio, ranked #169.

Claro Advisors first reported a position in VRTX in Q4 2018 and has held it in 15 quarters since. The position peaked at $1.42M in Q1 2025. 1,356 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Claro Advisors held 2,154 shares of Vertex Pharmaceuticals worth $1.13M as of Q3 2026.
  • Claro Advisors bought 709 Vertex Pharmaceuticals shares in Q3 2026, an estimated $363K.
  • Vertex Pharmaceuticals made up 0.11% of Claro Advisors's portfolio in Q3 2026, its #169 holding.
  • Claro Advisors first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 15 quarters since.
  • Claro Advisors's Vertex Pharmaceuticals position peaked at $1.42M in Q1 2025.
  • 1,356 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Claro Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.